Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

134.02
Delayed Data
As of 4:00pm ET
 +2.81 / +2.14%
Today’s Change
60.30
Today|||52-Week Range
134.97
+33.66%
Year-to-Date
5 Toxic Stocks to Abandon or Play Short Right Now
7:17am / Zacks.com - Paid Partner Content
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Bioscienc...
Feb 22 / GuruFocus News - Paid Partner Content
Here's Why Incyte Rose as Much as 8% Today
Feb 24 / MotleyFool.com - Paid Partner Content
Troubling Trial Data Weighed on Agenus Inc Stock Today
Feb 22 / MotleyFool.com - Paid Partner Content
Better Buy: Juno Therapeutics vs. Incyte
Feb 24 / MotleyFool.com - Paid Partner Content
What's Driving Lilly's (LLY) Shares after 2016 Decline?
Feb 16 / Zacks.com - Paid Partner Content
Biotech Movers: Cempra Flys High On Phase Three Results
Feb 24 / TheStreet.com - Paid Partner Content
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
Feb 15 / Zacks.com - Paid Partner Content
3 All-or-Nothing Stocks We're Closely Watching
Feb 23 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Present...
Feb 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close131.21
Today’s open131.88
Day’s range130.24 - 134.97
Volume33,191,369
Average volume (3 months)1,467,512
Market cap$24.9B
Dividend yield--
Data as of 4:00pm ET, 02/27/2017

Growth & Valuation

Earnings growth (last year)+1,700.00%
Earnings growth (this year)-5.06%
Earnings growth (next 5 years)+95.15%
Revenue growth (last year)+46.70%
P/E ratio248.2
Price/Sales17.60
Price/Book59.07

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc-0.05-0.09%
MYLMylan NV+0.28+0.66%
BAXBaxter International...-0.05-0.10%
VRTXVertex Pharmaceutica...+2.83+3.29%
Data as of 4:00pm ET, 02/27/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)-$0.67
Annual revenue (last year)$1.1B
Annual profit (last year)$104.2M
Net profit margin9.43%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts


Search for Jobs